financetom
Business
financetom
/
Business
/
STLLR Gold Up as Raises $36.6 Million Via Private Placement Financing; Eric Sprott Increases Stake by 14.9%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
STLLR Gold Up as Raises $36.6 Million Via Private Placement Financing; Eric Sprott Increases Stake by 14.9%
Oct 15, 2025 11:45 AM

02:22 PM EDT, 10/15/2025 (MT Newswires) -- STLLR Gold ( STLRF ) shares was last seen up 5.9% on Wednesday after it closed a bought-deal and concurrent private placement of shares, raising $36.6 million.

The company sold underwriters 2.79-million charity flow-through shares priced at $1.792 each; 3.25-million flow-through shares priced at $1.54 each; and 5.17-million common shares priced at $1.28 each, raising $16.61 million in total.

A concurrent non-brokered private placement of 11.72-million shares to mining financier Eric Sprott raised $15 million, while Agnico Eagle Mines (AEM.TO) separately acquired 3.91-million common shares at $1.28 apiece for $5 million.

The company said as a result of the offering, Sprott, through 2176423 Ontario Ltd., increased his ownership interest in the company to 14.9% while Agnico Eagle increased its stake in the company to about 11%.

"This financing strengthens our ability to advance the Tower Gold and Hollinger Tailings projects in the Timmins Mining Camp," said Chief Executive Keyvan Salehi.

Proceeds from the sale of the common shares will be used for operating expenses and for general corporate and working capital needs. Proceeds from the sale of the FT shares and Premium FT shares will be used for exploration expenditures on its properties.

Shares of the company were last seen up $0.09 at $1.62 on the Toronto Stock Exchange.

Price: 1.62, Change: +0.09, Percent Change: +5.88

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Estee Lauder Companies Insider Sold Shares Worth $476,971, According to a Recent SEC Filing
Estee Lauder Companies Insider Sold Shares Worth $476,971, According to a Recent SEC Filing
Nov 19, 2025
12:41 PM EST, 11/19/2025 (MT Newswires) -- Meridith Webster, Executive Vice President, Global Communications and Public Affairs, on November 18, 2025, sold 5,430 shares in Estee Lauder Companies ( EL ) for $476,971. SEC Filing: https://www.sec.gov/Archives/edgar/data/1001250/000185714625000005/xslF345X05/wk-form4_1763573858.xml Price: 86.60, Change: -1.46, Percent Change: -1.66 ...
Energy Fuels Insider Sold Shares Worth $389,500, According to a Recent SEC Filing
Energy Fuels Insider Sold Shares Worth $389,500, According to a Recent SEC Filing
Nov 19, 2025
12:38 PM EST, 11/19/2025 (MT Newswires) -- Curtis Moore, Senior Vice President, Marketing & Corporate Development, on November 17, 2025, sold 25,000 shares in Energy Fuels ( UUUU ) for $389,500. Following the Form 4 filing with the SEC, Moore has control over a total of 119,193 common shares of the company, with 119,193 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1385849/000138584925000048/xslF345X05/primary_doc.xml...
Adobe, Qualcomm partner with Humain on generative AI for Middle East
Adobe, Qualcomm partner with Humain on generative AI for Middle East
Nov 19, 2025
SAN FRANCISCO, Nov 19 (Reuters) - Adobe and Qualcomm ( QCOM ) said on Wednesday they are partnering with Humain, the artificial intelligence firm backed by Saudi Arabia's sovereign wealth fund, to help the AI company develop tools for generating content in Arabic and for the broader Middle East. The deal is one of several expected on Wednesday at a...
Why Is Agios Pharmaceuticals Stock Sinking Today?
Why Is Agios Pharmaceuticals Stock Sinking Today?
Nov 19, 2025
Agios Pharmaceuticals Inc. ( AGIO ) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease. AGIO is testing key support levels. See what the experts say here The trial met its primary endpoint of hemoglobin response, with mitapivat demonstrating a statistically significant improvement compared to placebo. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved